Diabetic Macular Edema / Diabetic Retinopathy – Unmet Need – Detailed, expanded analysis: diabetic macular edema (US & EU)

Diabetic macular edema (DME) is caused by diabetes and is characterized by leaking fluid from abnormal blood vessels in the eye; this fluid can lead to swelling of the macula and visual impairment. Intravitreal vascular endothelial growth factor (VEGF) inhibitors, such as Regeneron / Bayer’s Eylea, Roche / Novartis’s Lucentis, and Roche’s Avastin, are the most common pharmacotherapies for treating DME, owing to their proven efficacy and safety. AbbVie’s Ozurdex and Alimera Sciences’ Iluvien, two long-acting corticosteroid implants, are also used to treat DME. However, these drugs all have clinical shortcomings in terms of efficacy, safety, and/or delivery, creating opportunities for new and improved alternatives. Our content examines the key treatment drivers and analyzes the greatest areas of unmet need, thereby presenting the opportunities in this space.


  • What are the treatment drivers and goals for DME?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for DME?
  • What are the prevailing areas of unmet need and opportunity in DME?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European ophthalmologists for a hypothetical new DME drug?


Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European ophthalmologists fielded in March 2022

Key companies: Roche, Regeneron, Novartis, Bayer, AbbVie, Alimera Sciences

Key drugs: Eylea, Lucentis, Avastin, Ozurdex, Iluvien

Table of contents

launch Related Market Assessment Reports